Myelodysplastic Syndromes (MDS) cause a failure of the bone marrow, which does not produce enough blood cells (red cells, white cells and platelets). This is because the bone marrow contains too many abnormal cells (dysplastic cells) which function poorly.
Many patients with MDS, do not produce enough red blood cells, which leads to anaemia. This means that they receive regular blood transfusions to treat the anaemia and alleviate symptoms. However, blood is rich in iron and repeated transfusions may cause a buildup
of excess iron. Although iron is an essential part of the blood, an excess of iron may affect the way the organs in the body function. This includes the liver and heart. This situation is called iron overload. The aim of this study is test how effective, safe and tolerable a drug called Deferasirox (also called Exjade®) is, when used to treat rising iron levels, in patients with MDS.
Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible
| Chief Investigator: |
Dr Dominic Culligan |
| Sponsor: |
University of Birmingham |
| Funders: |
Bloodwise (Non-TAP) |
| Disease Site: |
Myelodysplastic Syndromes |
| Trial Type: |
Clinical Trial of an Investigational Medicinal Product |
| Status: |
In Follow up |
| UKCRN Study ID: (if applicable) |
13706
|
| Open to new sites? |
No |
| Recruitment start date: |
19-Jun-2013 |
| Recruitment end date |
30-Nov-2015 |
| CRCTU Trial Management Team: |
Haematology |
| Trial E-mail Address: |
de-iron@trials.bham.ac.uk |